BIOMAT Database Logo BIOMAT Database Logo

Long-term use of hydroxyurea for sickle cell anemia. 2003

Derrick W Spell

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder
D000986 Antisickling Agents Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions. Desickling Agents,Agents, Antisickling,Agents, Desickling

Related Publications

Derrick W Spell
Long-term use of hydroxyurea for sickle cell anemia.
August 2003, JAMA,
Derrick W Spell
Long-term use of hydroxyurea for sickle cell anemia.
August 2003, JAMA,
Derrick W Spell
Long-term use of hydroxyurea for sickle cell anemia.
August 2003, JAMA,
Derrick W Spell
Hydroxyurea for sickle cell anemia.
July 2008, The New England journal of medicine,
Derrick W Spell
Hydroxyurea for sickle cell anemia.
July 2008, The New England journal of medicine,
Derrick W Spell
Hydroxyurea marketed for sickle cell anemia.
May 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Derrick W Spell
Hydroxyurea therapy for sickle cell anemia.
January 2015, Expert opinion on drug safety,
Derrick W Spell
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.
October 2005, Blood,
Derrick W Spell
Hydroxyurea use among children with sickle cell anemia.
June 2019, Pediatric blood & cancer,
Derrick W Spell
Hydroxyurea as treatment for sickle cell anemia.
June 1991, Hematology/oncology clinics of North America,
Copied contents to your clipboard!